Aurinia Pharmaceuticals
AUPH
199 hedge funds and large institutions have $510M invested in Aurinia Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 54 increasing their positions, 44 reducing their positions, and 26 closing their positions.
65% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 26
51% more call options, than puts
Call options by funds: $33.1M | Put options by funds: $22M
23% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 44
8% more funds holding
Funds holding: 184 → 199 (+15)
5.31% more ownership
Funds ownership: 30.48% → 35.79% (+5.3%)
4% less capital invested
Capital invested by funds: $533M → $510M (-$22.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$66.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$20.8M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.8M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$10.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.5M |
| 2 |
Renaissance Technologies
New York
|
-$12.2M |
| 3 |
SG Americas Securities
New York
|
-$8.71M |
| 4 |
Millennium Management
New York
|
-$8.08M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$4.8M |
AUPH Hedge Fund Activity: Q2 2022 in Review
199 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2022, worth a combined $510M — down 4.3% from $533M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new AUPH positions and 26 closed out — a net gain of 17 holders — while 54 added to existing stakes and 44 trimmed.
The largest buyer was BlackRock, adding an estimated $66.9M. The largest seller was Fidelity Investments, cutting an estimated $17.5M.
- 199 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2022, up from 184 in Q1 2022.
- Funds reported $510M of Aurinia Pharmaceuticals stock for Q2 2022, down 4.3% quarter-over-quarter.
- 43 funds opened new Aurinia Pharmaceuticals positions in Q2 2022 and 26 closed out, a net change of +17 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2022 was BlackRock, an estimated $66.9M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2022 was Fidelity Investments, an estimated $17.5M sold.
Based on aggregated 13F filings for Q2 2022.